Stryker Corporation Q2 2026 Earnings Recap

Stryker's stock fell 7.5% following the earnings release as investors reacted negatively to meaningful supply disruptions in the peripheral vascular business that caused significant lost sales and pressured margins despite solid overall organic growth.

Key Takeaways

• Reported 9% organic sales growth driven by strong performances in MedSurg, Neurotechnology, and Orthopedics.
• Supply chain issues in the peripheral vascular segment led to a considerable backlog and lost sales; management expects backorders to normalize by end of Q3.
• Adjusted EPS grew 17.9%, benefiting from operational execution and tariff-related cost benefits, though offset in part by margin pressure in disrupted segments.
• US organic growth was 9% with double-digit growth in medical, trauma extremities, and endoscopy businesses; Instruments grew 8.4% in the US.
• International organic growth stood at 8.9%, supported by strong demand in diverse markets including Australia, Germany, and Japan.